Latest filings (excl ownership)
15-12B
Securities registration termination
10 Jan 22
EFFECT
Notice of effectiveness
3 Jan 22
EFFECT
Notice of effectiveness
3 Jan 22
EFFECT
Notice of effectiveness
3 Jan 22
EFFECT
Notice of effectiveness
3 Jan 22
POSASR
Automatic shelf registration (post-effective amendment)
28 Dec 21
POS AM
Prospectus update (post-effective amendment)
28 Dec 21
POS AM
Prospectus update (post-effective amendment)
28 Dec 21
POS AM
Prospectus update (post-effective amendment)
28 Dec 21
POS AM
Prospectus update (post-effective amendment)
28 Dec 21
S-8 POS
Registration of securities for employees (post-effective amendment)
28 Dec 21
S-8 POS
Registration of securities for employees (post-effective amendment)
28 Dec 21
S-8 POS
Registration of securities for employees (post-effective amendment)
28 Dec 21
S-8 POS
Registration of securities for employees (post-effective amendment)
28 Dec 21
S-8 POS
Registration of securities for employees (post-effective amendment)
28 Dec 21
S-8 POS
Registration of securities for employees (post-effective amendment)
28 Dec 21
SC 14D9/A
Tender offer solicitation (amended)
28 Dec 21
SC TO-T/A
Third party tender offer statement (amended)
28 Dec 21
25-NSE
Exchange delisting
28 Dec 21
8-K
Novo Nordisk Announces Completion of Dicerna Pharmaceuticals Acquisition
28 Dec 21
SC TO-T/A
Third party tender offer statement (amended)
27 Dec 21
SC 14D9/A
Tender offer solicitation (amended)
27 Dec 21
SC 14D9/A
Tender offer solicitation (amended)
15 Dec 21
SC TO-T/A
Third party tender offer statement (amended)
8 Dec 21
SC 14D9/A
Tender offer solicitation (amended)
8 Dec 21
SC 14D9
Tender offer solicitation
24 Nov 21
SC TO-T
Third party tender offer statement
24 Nov 21
SC TO-C
Information about tender offer
18 Nov 21
SC14D9C
Written communication relating to third party tender offer
18 Nov 21
SC14D9C
Written communication relating to third party tender offer
18 Nov 21
8-K
Novo Nordisk to Acquire Dicerna
18 Nov 21
10-Q
2021 Q3
Quarterly report
9 Nov 21
8-K
Dicerna Announces Third Quarter 2021 Financial Results and Provides a Business Update
9 Nov 21
10-Q
2021 Q2
Quarterly report
9 Aug 21
8-K
Dicerna Announces Second Quarter 2021 Financial Results and Provides a Business Update
9 Aug 21
8-K
Dicerna Reports Positive Top-Line Results From PHYOX™2 Pivotal Clinical Trial of Nedosiran for the Treatment of Primary Hyperoxaluria
6 Aug 21
8-K
Submission of Matters to a Vote of Security Holders
4 Jun 21
424B5
Prospectus supplement for primary offering
6 May 21
10-Q
2021 Q1
Quarterly report
6 May 21
8-K
Dicerna Announces First Quarter 2021 Financial Results and Provides a Business Update
6 May 21
Latest ownership filings
SC 13G/A
BALYASNY ASSET MANAGEMENT LLC
14 Feb 22
4
Adam Koppel
29 Dec 21
4
Ling Zeng
29 Dec 21
4
James B Weissman
29 Dec 21
4
Cynthia Smith
29 Dec 21
4
Douglas W. Pagan
29 Dec 21
4
MARC D KOZIN
29 Dec 21
4
STEPHEN J HOFFMAN
29 Dec 21
4
PATRICK M. GRAY
29 Dec 21
4
Martin I Freed
29 Dec 21
4
DOUGLAS FAMBROUGH
29 Dec 21
4
Stephen K Doberstein
29 Dec 21
4
Robert D. Ciappenelli
29 Dec 21
4
J KEVIN BUCHI
29 Dec 21
4
Bob D Brown
29 Dec 21
4
Shreeram Aradhye
29 Dec 21
4
Douglas W. Pagan
17 Dec 21
4
Robert D. Ciappenelli
17 Dec 21
4
Shreeram Aradhye
17 Dec 21
4
James B Weissman
17 Dec 21
4
DOUGLAS FAMBROUGH
17 Dec 21
4
Bob D Brown
17 Dec 21
4
Ling Zeng
17 Dec 21
4
Robert D. Ciappenelli
14 Dec 21
4
DOUGLAS FAMBROUGH
13 Dec 21
SC 13G
BALYASNY ASSET MANAGEMENT LLC
3 Dec 21
4
Bob D Brown
22 Nov 21
4
Bob D Brown
21 Sep 21
4
Ling Zeng
17 Sep 21
4
Shreeram Aradhye
17 Sep 21
4
DOUGLAS FAMBROUGH
10 Aug 21
4
MARC D KOZIN
10 Aug 21
4
Bob D Brown
3 Aug 21
4
Regina M. Paglia
8 Jul 21
4
James B Weissman
8 Jul 21
4
Bob D Brown
6 Jul 21
4
Regina M. Paglia
29 Jun 21
4
Regina M. Paglia
24 Jun 21
4
Regina M. Paglia
22 Jun 21
4
Douglas W. Pagan
17 Jun 21